Security record · archived quarter
VRTX
Vertex Pharmaceuticals Incorporated · Healthcare · Biotechnology
3Tracked holders
0Δ holders
1.30MShares held
$664.72MReported value
+0New positions
−1Exits
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2026
Ownership over time
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | 0 | 1.30M | $664.72M | n/a | −1 |
| Q2 2026 | 173 | -1 | 210.42M | $104.38B | +5 | −7 |
| Q1 2026 | 178 | 0 | 208.95M | $93.29B | +5 | −6 |
| Q4 2025 | 177 | -1 | 219.78M | $99.62B | +2 | −2 |
| Q3 2025 | 26 | +1 | 120.93M | $47.35B | +1 | −1 |
| Q2 2025 | 23 | +1 | 112.15M | $49.92B | +3 | −2 |
| Q1 2025 | 19 | -2 | 60.41M | $29.28B | n/a | −2 |
| Q4 2024 | 21 | +1 | 60.08M | $24.19B | +1 | n/a |
| Q3 2024 | 19 | 0 | 46.24M | $21.49B | n/a | n/a |
| Q2 2024 | 19 | n/a | 46.47M | $21.77B | n/a | n/a |
Who holds it · Q3 2026
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Assenagon Asset Management S.A. | 1.22M | -19.7% | $637.47M | 0.6% | ▼ Trim | 4 | SEC ↗ |
| 2 | Wealth Enhancement Advisory… | 70.92K | +54.5% | $22.42M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 3 | TD Waterhouse Canada Inc. | 9.51K | -30.3% | $4.83M | 0.0% | ▼ Trim | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Robeco Institutional Asset… | $200.88M | was 0.2% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 1,678 holders, 225.07M shares, $98.10B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
Frequently co-owned
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q3 2026 ·
Methodology ·
Get this via the API